CA2097016A1 - Pharmaceutical compounds - Google Patents

Pharmaceutical compounds

Info

Publication number: CA2097016A1
Authority: CA; Canada
Prior art keywords: alkyl; methyl; compounds; loh; benzodiazepine
Prior art date: 1992-05-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002097016A

Other languages

English (en)

French (fr)

Inventor

John Fairhurst

Terrence Michael Hotten

David Edward Tupper

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Lilly Industries Ltd

Original Assignee

Lilly Industries Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-05-29

Filing date

1993-05-26

Publication date

1993-11-30

1992-05-29 Priority claimed from GB929211379A external-priority patent/GB9211379D0/en

1993-04-30 Priority claimed from GB939309025A external-priority patent/GB9309025D0/en

1993-05-26 Application filed by Lilly Industries Ltd filed Critical Lilly Industries Ltd

1993-11-30 Publication of CA2097016A1 publication Critical patent/CA2097016A1/en

Status Abandoned legal-status Critical Current

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 42
150000003839 salts Chemical class 0.000 claims abstract description 16
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract description 12
239000001257 hydrogen Substances 0.000 claims abstract description 8
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 8
125000000304 alkynyl group Chemical group 0.000 claims abstract description 7
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 7
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract description 4
125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 4
125000006374 C2-C10 alkenyl group Chemical group 0.000 claims abstract description 3
125000000008 (C1-C10) alkyl group Chemical group 0.000 claims abstract 2
125000001475 halogen functional group Chemical group 0.000 claims abstract 2
125000000217 alkyl group Chemical group 0.000 claims description 18
239000003085 diluting agent Substances 0.000 claims description 5
238000000034 method Methods 0.000 claims description 5
125000003342 alkenyl group Chemical group 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 3
230000002152 alkylating effect Effects 0.000 claims description 2
150000001450 anions Chemical class 0.000 claims description 2
125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 1
125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 1
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 14
229940049706 benzodiazepine Drugs 0.000 description 14
239000000203 mixture Substances 0.000 description 10
-1 prop-2-enyl Chemical group 0.000 description 10
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
239000004480 active ingredient Substances 0.000 description 8
125000005843 halogen group Chemical group 0.000 description 7
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
229920002472 Starch Polymers 0.000 description 6
230000000694 effects Effects 0.000 description 6
238000009472 formulation Methods 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
235000019698 starch Nutrition 0.000 description 6
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 5
239000000243 solution Substances 0.000 description 5
239000008107 starch Substances 0.000 description 5
208000019901 Anxiety disease Diseases 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
239000002775 capsule Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
238000012360 testing method Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
208000028017 Psychotic disease Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000002585 base Substances 0.000 description 3
210000003169 central nervous system Anatomy 0.000 description 3
125000001309 chloro group Chemical group Cl* 0.000 description 3
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
102000035037 5-HT3 receptors Human genes 0.000 description 2
108091005477 5-HT3 receptors Proteins 0.000 description 2
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
229940100198 alkylating agent Drugs 0.000 description 2
239000002168 alkylating agent Substances 0.000 description 2
239000000908 ammonium hydroxide Substances 0.000 description 2
230000036506 anxiety Effects 0.000 description 2
239000002249 anxiolytic agent Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
230000009969 flowable effect Effects 0.000 description 2
125000001153 fluoro group Chemical group F* 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
238000010255 intramuscular injection Methods 0.000 description 2
239000007927 intramuscular injection Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
229920001296 polysiloxane Polymers 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
239000007858 starting material Substances 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
239000003826 tablet Substances 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
XUDUTRMKKYUAKI-UHFFFAOYSA-N 3-[1-(1-phenylethyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2C(NC3=CC=CC=C32)=O)CCN1C(C)C1=CC=CC=C1 XUDUTRMKKYUAKI-UHFFFAOYSA-N 0.000 description 1
125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
102000035038 5-HT1 receptors Human genes 0.000 description 1
108091005478 5-HT1 receptors Proteins 0.000 description 1
102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
108091005479 5-HT2 receptors Proteins 0.000 description 1
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
235000006491 Acacia senegal Nutrition 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
102000004076 Dopamine D1 Receptors Human genes 0.000 description 1
108090000511 Dopamine D1 Receptors Proteins 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010026749 Mania Diseases 0.000 description 1
208000026139 Memory disease Diseases 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
208000020186 Schizophreniform disease Diseases 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
239000003513 alkali Substances 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
230000003474 anti-emetic effect Effects 0.000 description 1
230000000561 anti-psychotic effect Effects 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
150000004982 aromatic amines Chemical class 0.000 description 1
230000006399 behavior Effects 0.000 description 1
RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
239000012965 benzophenone Substances 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
239000000920 calcium hydroxide Substances 0.000 description 1
229910001861 calcium hydroxide Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
230000009194 climbing Effects 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003480 eluent Substances 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000006870 function Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229960003878 haloperidol Drugs 0.000 description 1
150000004679 hydroxides Chemical class 0.000 description 1
UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000011344 liquid material Substances 0.000 description 1
159000000002 lithium salts Chemical group 0.000 description 1
231100000863 loss of memory Toxicity 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
206010027175 memory impairment Diseases 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical group COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
239000003176 neuroleptic agent Substances 0.000 description 1
230000000701 neuroleptic effect Effects 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
208000019906 panic disease Diseases 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
150000003016 phosphoric acids Chemical class 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000004044 response Effects 0.000 description 1
239000012056 semi-solid material Substances 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000011343 solid material Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
125000004953 trihalomethyl group Chemical group 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Addiction (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

CA002097016A 1992-05-29 1993-05-26 Pharmaceutical compounds Abandoned CA2097016A1 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB929211379A GB9211379D0 (en)	1992-05-29	1992-05-29	Pharmaceutical compounds
GB9211379.4		1992-05-29
GB939309025A GB9309025D0 (en)	1993-04-30	1993-04-30	Pharmaceutical compounds
GB9309025.6		1993-04-30

Publications (1)

Publication Number	Publication Date
CA2097016A1 true CA2097016A1 (en)	1993-11-30

Family

ID=26300951

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002097016A Abandoned CA2097016A1 (en)	1992-05-29	1993-05-26	Pharmaceutical compounds

Country Status (21)

Country	Link
EP (1)	EP0582368B1 (2)
JP (1)	JP3219541B2 (2)
CN (1)	CN1043994C (2)
AT (1)	ATE198891T1 (2)
AU (1)	AU668159B2 (2)
CA (1)	CA2097016A1 (2)
CZ (1)	CZ282783B6 (2)
DE (1)	DE69329887T2 (2)
DK (1)	DK0582368T3 (2)
ES (1)	ES2153373T3 (2)
FI (1)	FI101538B (2)
GR (1)	GR3035587T3 (2)
HU (1)	HU218278B (2)
IL (1)	IL105827A (2)
MX (1)	MX9303124A (2)
MY (1)	MY109943A (2)
NO (1)	NO305125B1 (2)
NZ (1)	NZ247703A (2)
PT (1)	PT582368E (2)
RU (1)	RU2125574C1 (2)
TW (1)	TW268005B (2)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5457101A (en) *	1994-06-03	1995-10-10	Eli Lilly And Company	Thieno[1,5]benzoidiazepine use
US5574028A (en) *	1994-10-31	1996-11-12	Eli Lilly And Company	Method for treating anxiety
CR5278A (es) *	1995-03-24	1996-07-04	Lilly Co Eli	Formulacion oral de 2-metil-tieno-benzodiacepina
EG24221A (en) *	1995-03-24	2008-11-10	Lilly Co Eli	Process for preparing olanzapine
EG23659A (en) *	1995-03-24	2007-03-26	Lilly Co Eli	Process and crystal forms of methyl-thieno-benzodiazepine
US5891461A (en) *	1995-09-14	1999-04-06	Cygnus, Inc.	Transdermal administration of olanzapine
EP0932407A4 (en) *	1996-03-25	2002-04-24	Lilly Co Eli	TECHNIQUE FOR TREATING MIGRAINE PAIN
CN1494907A (zh) *	1996-03-25	2004-05-12		治疗疼痛的药物组合物
IL126064A0 (en) *	1996-03-25	1999-05-09	Lilly Co Eli	Method for treating pain
TR199900639T2 (xx)	1996-09-23	1999-06-21	Eli Lilly And Company	Olanzapin dihidrat D.
ZA978515B (en) *	1996-09-23	1999-03-23	Lilly Co Eli	Intermediates and process for preparing olanzapine
CA2266448A1 (en) *	1996-09-24	1998-04-02	Eli Lilly And Company	Coated particle formulation
RU2185383C1 (ru) *	2001-05-22	2002-07-20	Институт молекулярной генетики РАН	ВЫСОКОМЕЧЕННЫЙ ТРИТИЕМ 2-МЕТИЛ-4-(4-МЕТИЛ-1-ПИПЕРАЗИНИЛ)-10Н-ТИЕНО[2,3-b][1,5]БЕНЗОДИАЗЕПИН
CN110054694B (zh)	2012-08-21	2024-02-20	詹森药业有限公司	阿立哌唑半抗原的抗体及其用途
CA2882454C (en) *	2012-08-21	2020-08-11	Matthew Garrett DONAHUE	Haptens of olanzapine
CA2882489A1 (en)	2012-08-21	2014-02-27	Ortho-Clinical Diagnostics, Inc.	Antibodies to paliperidone haptens and use thereof
PT3462173T (pt)	2012-08-21	2021-04-28	Janssen Pharmaceutica Nv	Anticorpos contra risperidona e utilização dos mesmos
EP2888263B1 (en)	2012-08-21	2018-05-09	Janssen Pharmaceutica NV	Haptens of risperidone and paliperidone
US20140057303A1 (en)	2012-08-21	2014-02-27	Janssen Pharmaceutica Nv	Antibodies to Olanzapine Haptens and Use Thereof
AU2013305879B2 (en)	2012-08-21	2017-10-12	Saladax Biomedical Inc.	Antibodies to aripiprazole and use thereof
PL3321254T3 (pl)	2012-08-21	2021-01-11	Janssen Pharmaceutica Nv	Hapteny arypiprazolu i ich zastosowanie w testach immunologicznych
AU2013305930B2 (en)	2012-08-21	2017-08-24	Saladax Biomedical Inc.	Haptens of paliperidone
HK1211958A1 (en)	2012-08-21	2016-06-03	Ortho-Clinical Diagnostics, Inc.	Antibodies to paliperidone and use thereof
WO2014031645A1 (en)	2012-08-21	2014-02-27	Ortho-Clinical Diagnostics, Inc	Antibodies to risperidone haptens and use thereof
JP6216926B2 (ja)	2012-08-21	2017-10-25	ヤンセンファーマシューティカエヌ．ベー．	オランザピンに対する抗体及びその使用
EP3305784B1 (en)	2012-08-21	2020-08-12	Janssen Pharmaceutica NV	Haptens of quetiapine for use in immunoassays
PL3333195T3 (pl)	2012-08-21	2021-02-22	Janssen Pharmaceutica Nv	Przeciwciała względem kwetiapiny i ich zastosowania
PL3663317T3 (pl)	2012-08-21	2023-06-05	Janssen Pharmaceutica Nv	Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
WO2017106508A1 (en)	2015-12-17	2017-06-22	Janssen Pharmaceutica Nv	Antibodies to quetiapine and use thereof
AU2016372069A1 (en)	2015-12-17	2018-06-07	Saladax Biomedical Inc.	Antibodies to risperidone and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3962248A (en) *	1972-04-04	1976-06-08	Sandoz, Inc.	Process for making 11-piperazino-diazepines, oxazepines, thiazepines and azepines
CH569731A5 (2) *	1972-04-04	1975-11-28	Wander Ag Dr A
SU629879A3 (ru) *	1974-11-26	1978-10-25	Лилли Индастриз Лимитед, (Фирма)	Способ получени тиено(1,5) бензодиазепинов или их солей
US4061752A (en) *	1975-08-06	1977-12-06	Sandoz Ltd.	6-Piperazino-11-methylene-dibenzazepines[b,e]
DE2641378A1 (de) *	1975-09-24	1977-04-07	Sandoz Ag	Neue organische verbindungen, ihre verwendung und herstellung
CH624682A5 (2) *	1976-11-10	1981-08-14	Sandoz Ag
US4761411A (en) *	1983-05-18	1988-08-02	Hoechst-Roussel Pharmaceuticals Inc.	Dihydrobenzopyrrolobenzodiazepines useful for treating pyschoses
GB9009229D0 (en) *	1990-04-25	1990-06-20	Lilly Industries Ltd	Pharmaceutical compounds

1993
- 1993-05-26 AU AU39807/93A patent/AU668159B2/en not_active Ceased
- 1993-05-26 EP EP93304102A patent/EP0582368B1/en not_active Expired - Lifetime
- 1993-05-26 NZ NZ247703A patent/NZ247703A/en unknown
- 1993-05-26 DK DK93304102T patent/DK0582368T3/da active
- 1993-05-26 PT PT93304102T patent/PT582368E/pt unknown
- 1993-05-26 AT AT93304102T patent/ATE198891T1/de not_active IP Right Cessation
- 1993-05-26 ES ES93304102T patent/ES2153373T3/es not_active Expired - Lifetime
- 1993-05-26 NO NO931917A patent/NO305125B1/no not_active IP Right Cessation
- 1993-05-26 CA CA002097016A patent/CA2097016A1/en not_active Abandoned
- 1993-05-26 DE DE69329887T patent/DE69329887T2/de not_active Expired - Fee Related
- 1993-05-26 TW TW082104161A patent/TW268005B/zh active
- 1993-05-27 MX MX9303124A patent/MX9303124A/es not_active IP Right Cessation
- 1993-05-28 CZ CZ931024A patent/CZ282783B6/cs not_active IP Right Cessation
- 1993-05-28 HU HU9301579A patent/HU218278B/hu not_active IP Right Cessation
- 1993-05-28 IL IL10582793A patent/IL105827A/xx not_active IP Right Cessation
- 1993-05-28 CN CN93108212A patent/CN1043994C/zh not_active Expired - Fee Related
- 1993-05-28 MY MYPI93001036A patent/MY109943A/en unknown
- 1993-05-28 RU RU93005057A patent/RU2125574C1/ru active
- 1993-05-28 JP JP12642993A patent/JP3219541B2/ja not_active Expired - Fee Related
- 1993-05-28 FI FI932445A patent/FI101538B/fi active
2001
- 2001-03-15 GR GR20010400431T patent/GR3035587T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
CZ282783B6 (cs)	1997-10-15
IL105827A (en)	1997-02-18
JP3219541B2 (ja)	2001-10-15
CN1085903A (zh)	1994-04-27
MY109943A (en)	1997-10-31
ES2153373T3 (es)	2001-03-01
FI932445L (fi)	1993-11-30
DK0582368T3 (da)	2001-02-05
IL105827A0 (en)	1993-09-22
RU2125574C1 (ru)	1999-01-27
NZ247703A (en)	1995-07-26
CZ102493A3 (en)	1993-12-15
EP0582368A1 (en)	1994-02-09
AU668159B2 (en)	1996-04-26
CN1043994C (zh)	1999-07-07
FI101538B1 (fi)	1998-07-15
AU3980793A (en)	1993-12-02
HU9301579D0 (en)	1993-09-28
ATE198891T1 (de)	2001-02-15
NO931917D0 (no)	1993-05-26
DE69329887D1 (de)	2001-03-01
NO931917L (no)	1993-11-30
FI101538B (fi)	1998-07-15
FI932445A0 (fi)	1993-05-28
JPH0687862A (ja)	1994-03-29
GR3035587T3 (en)	2001-06-29
PT582368E (pt)	2001-05-31
HUT66180A (en)	1994-09-28
MX9303124A (es)	1993-11-01
EP0582368B1 (en)	2001-01-24
TW268005B (2)	1996-01-11
DE69329887T2 (de)	2001-05-23
NO305125B1 (no)	1999-04-06
HU218278B (en)	2000-07-28

Legal Events

Date	Code	Title	Description
2000-03-01	EEER	Examination request
2003-05-26	FZDE	Discontinued

Publication	Publication Date	Title
EP0582368B1 (en)	2001-01-24	Thienobenzodiazepine derivatives for treatment of CNS disorders
US6034078A (en)	2000-03-07	Thienobenzodiazepine compounds
US6008216A (en)	1999-12-28	Process for preparing 2-methyl-thieno-benzodiazepine
US5229382A (en)	1993-07-20	2-methyl-thieno-benzodiazepine
US3558606A (en)	1971-01-26	Tetrahydrobenzothienodiazepinone compounds
US4963558A (en)	1990-10-16	Pyrazolo-[3,4-g]isoquinoline derivatives useful to treat CNS disorders
SK279196B6 (sk)	1998-07-08	2-metyl-10-(4-metyl-1-piperazinyl)-4h-tieno-[2,3-b
EP0836688A2 (de)	1998-04-22	Rotierendes ventil mit schrägem zugang
CZ443199A3 (cs)	2000-06-14	3-substituované 3,4-dihydrothieno[2,3-d] pyrimidinové deriváty, jejich příprava a použití
KR20110093948A (ko)	2011-08-18	신규 헤테로시클리덴 아세트아미드 유도체
US3953430A (en)	1976-04-27	Substituted benzodiazepin-10-ones and method of use
AU749539B2 (en)	2002-06-27	3-substituted 3,4,5,7-tetrahydro-pyrrolo3',4':4,5 thieno2,3-dpyrimidine derivatives, their preparation and use as 5HT antagonists
US6806283B2 (en)	2004-10-19	Selective serotonin receptor antagonists and therapeutic applications thereof
CN101228131B (zh)	2013-01-09	新的杂环亚基乙酰胺衍生物
KR100273622B1 (ko)	2000-12-15	티에노벤조디아제핀 유도체, 이의 제조방법 및 이를 포함하는 약제학적 제형
US4673674A (en)	1987-06-16	Diazepinoindoles useful for treating depression, schizophrenia, social withdrawal or anxiety and pharmaceutical compositions containing them
SK174399A3 (en)	2000-05-16	3-substituted pyrido [3',4':4,5] thieno [2,3-d] pyrimidine derivatives, and production and use of the same
JPH06505698A (ja)	1994-06-30	新規化合物
US4007272A (en)	1977-02-08	Substituted benzodiazepin-10-ones in treating pain and depression
US5028602A (en)	1991-07-02	Pharmaceutical compounds
JP5460620B2 (ja)	2014-04-02	アミノプロピリデン誘導体を含有する医薬
JP5503793B2 (ja)	2014-05-28	アミノプロピリデン誘導体
WO1996025416A1 (en)	1996-08-22	Thiophene compounds and medicinal use thereof
SA95160196B1 (ar)	2005-12-21	مركبات صيدلانية